Jenni Pilcher brings extensive financial leadership experience to Mach7 and 3D Medical, after spending the last 10 years as a senior executive in two leading Australian biotechnology companies. Most recently, Jenni was CFO and acting CEO for Alchemia, where following a strategic review and in preparation for returning capital to shareholders, she successfully executed the sale of the company’s lead asset, a company-wide re-organisation and major contract close-out negotiations.
Prior to Alchemia, Jenni spent eight years at Mesoblast as CFO and Company Secretary. As a member of Mesoblast’s executive team during a period of rapid growth for the company, Jenni was a lead executive in the successful completion of four capital raises totalling more than $230 million Australian dollars to international investors, a major out-licensing or core IP, corporate and product acquisitions and a contract manufacturing collaboration.
Jenni spent six years in senior finance roles with ASX 200 company Spotless Group and has extensive international experience including London Stock Exchange listed companies Medeva and FMCG giant Cadbury Schweppes and PWC New Zealand.
Jenni is a Chartered Accountant and an Associate of both the Institute of Chartered Secretaries & Administrators and the Governance Institute of Australia.
Upon completion of the proposed merger between Mach7 Technologies Pty Ltd and the ASX-listed company 3D Medical Limited, the company will change its name to Mach7 Technologies Limited and restructure the board and management team. It is expected the current managing director of Mach7 will be appointed Managing Director of the Mach7 group of companies and manage the group’s overseas operations and be supported by Jenni Pilcher in her capacity as CEO of the group’s Australian operations, including the 3D Medical business.
3DM’s Chairman, Dr Nigel Finch said, “After an extensive search we are delighted to announce that Jenni has agreed to join our team at this exciting time. Her experience in managing rapid growth within the healthcare sector, provides a valuable addition to our senior management team as we complete the merger with Mach7.”